Evidence map›Paper›PMID 34902619›Full record

ArticleBiomedical journal2022

Serum CA-125 and renal impairment in patients undergoing hyperthermic intraperitoneal chemotherapy.

David Bernal-Bello, Ignacio Guerra-Pérez, Laura Alegre-Zahonero

Open access · goldAbstract readLetterComment
In one paragraph

Article in Biomedical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. A concerted effort combating hepatitis.Biomedical journal · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

David Bernal-BelloDepartment of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain. Electronic address: david.bernal@salud.madrid.org.
Ignacio Guerra-PérezDepartment of Medical Specialities and Public Health, Universidad Rey Juan Carlos, Madrid, Spain.
Laura Alegre-ZahoneroDepartment of Medical Specialities and Public Health, Universidad Rey Juan Carlos, Madrid, Spain; Department of Nephrology, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Universidad Rey Juan Carlos · ESHospital Universitario de Fuenlabrada · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CisplatinHyperthermic Intraperitoneal ChemotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansSurvival RateCisplatinCA-125Drug toxicityHIPECPeritoneal permeabilityRenal failure

Identifiers

PMID34902619
PMCPMC9661511
OpenAlexW4200383011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.